Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Investigation Report on China Tacrolimus Market, 2009-2018 - New Market Report


Print article Print article
2014-03-11 14:36:40 - New Pharmaceuticals market report from CRI: "Investigation Report on China Tacrolimus Market, 2009-2018"

Tacrolimus, also named as "FK506" and "FR-900506", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name "Prograf". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China.

Since then, tacrolimus has become a first-line clinical drug to reduce organ rejection after liver and kidney transplantation in China.

The sales revenue is also increasing rapidly.

Full Report Details at
- www.fastmr.com/prod/782010_investigation_report_on_china_tacroli ..

For immunosuppressant is used in transplantation, a relatively special field, it requires high technical standard and large amount of investment in new compound development. The drugs available at present are thus very monopolistic, among which tacrolimus is with the most promising future and highest market value.

Since organ transplantation volume in China is only second to that of the U.S.A., a great amount of immunosuppressant is needed. The Chinese government has chosen this drug as clinical-preferred basic immunosuppressant. In recent years, the clinical application of tacrolimus continues to expand. It can treat many autoimmune diseases and is approved effective for immune diseases without specific medicine such as rheumatoid arthritis, kidney cirrhosis syndrome, atopic dermatitis and lupus. Therefore, the future is bright for medical use of tacrolimus.

Through this report, the readers can acquire the following information:

* Market Share of Major Tacrolimus Manufacturers in China Sample Hospitals
* Sales price of Tacrolimus in China Hospital Market
* Major Tacrolimus Manufacturers in China
* Share of Tacrolimus in Different Dosage Forms in China Hospital Market
* Prospect of China Tacrolimus Market

The following enterprises and people are recommended to purchase this report:

* Tacrolimus APIs and Finished Product Manufacturers
* Medical Institutions
* Investors/Research Institutes Focusing on Tacrolimus Market

Report Table of Contents:

Table of Contents
1 Relevant Concept of Tacrolimus
1.1 Indication
1.2 Sales Status on the Global Market

2 Market Overview of Tacrolimus in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Tacrolimus in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Tacrolimus Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Tacrolimus by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Tacrolimus in Hospital Market in China, 2013
6.1 Tacrolimus Produced by Fujisawa (IR)
6.2 Tacrolimus Produced by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
6.3 Tacrolimus Produced by Zhejiang Hisun Pharmaceutical Co., Ltd.
6.4 Tacrolimus Produced by Yamanouchi Pharmaceutical
6.5 Tacrolimus Produced by Sinopharm ChuanKang Pharmaceutical Co., Ltd.

7 Major Manufacturing Enterprises in China Tacrolimus Market, 2009-2013
7.1 Fujisawa (IR)
7.2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
7.3 Zhejiang Hisun Pharmaceutical Co., Ltd.
7.4 Yamanouchi Pharmaceutical
7.5 Sinopharm ChuanKang Pharmaceutical Co., Ltd.

8 Prospect of China Tacrolimus Market, 2014-2018
8.1 Demand immunosuppressant in China Market
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern
8.4 Generic Drugs in Research

Selected Charts
Chart Tacrolimus Products Approved to Market in China, 2014
Chart Sales Value of Tacrolimus in Global Market, 2009-2013
Chart Sales Value of Tacrolimus in Hospital Market in China, 2009-2013
Chart Sales Value of Tacrolimus by Region in China, 2009-2013
Chart Market Share of Tacrolimus Enterprises by Sales Value in China, 2009-2013
Chart Price of Tacrolimus Produced by Fujisawa (IR) in China Hospital Market, 2013
Chart Price of Tacrolimus Produced by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. in China Hospital Market, 2013
Chart Forecast on Market Size of Hospital-use Tacrolimus in China, 2014-2018
Chart Analysis and Forecast on Organ Transplant Amount in China

About CRI

CRI is a research and consulting company located in Shanghai, China, focusing on various industries and markets. It regularly produces a variety of market research reports, industry analytical reports publications covering 11 industries. It also provides customized industry research services for initial public offerings, corporate mergers and acquisitions, business development, market launch and financing. View more research from CRI at www.fastmr.com/catalog/publishers.aspx?pubid=1045

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com